Surgery Partners (NASDAQ:SGRY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Assessing Surgery Partners (SGRY) Valuation Following Fed-Driven Investor Optimism and Recent Share Price Rebound [Yahoo! Finance]
Surgery Partners (NASDAQ:SGRY) had its price target lowered by analysts at JPMorgan Chase & Co. from $27.00 to $20.00. They now have a "neutral" rating on the stock.
Surgery Partners (NASDAQ:SGRY) was given a new $18.00 price target on by analysts at Barclays PLC.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY